PYPD Polypid Ltd

$PYPD From shareholder perspective i have never been more bullish. They regained EU rights, and they prioritize new, faster, and cheaper PD01B program over any oncology. Waiting still more info but very happy if they pause oncology. Remember PD03A endpoint is strong preclinical package!

$PYPD An update on D-Plex during Investor Day can only mean that they have completed their CMC inspection and that no major issues were found. This is a good investment—LT

$PYPD It's just all about approval or CRL. If any approval, stock going to over $10 levels this year imo.

$PYPD it is a simple fact, if the pdufa outcome is likely and known, the actual news is a standard sell the news event if the outcome is not known or expected, there is potential value based on the dNPv

$PYPD If they announce "PAI completed with no issues" before FDA decision, i think $7 possible by PDUFA.

Quietest 36 day setup on the calendar right now? $PYPD goes to the FDA Nov 28 on D-PLEX100, a local doxycycline implant that cut surgical site infections 60 percent in Phase 3, p equals 0.0013. FDA flagged zero filing issues at acceptance and pulled the date a quarter early on Priority Review. EMA review started Oct 1 and the company just got its Europe rights back 5.13 with a hundred million dollar market cap into a first approval call. Azurity wrote 30 million up front to commercialize it ngl I do not know how much quieter a name gets

$PYPD spoke to company date is confirmed with fda for inspection but they are divulgeing nothing else not even the date

39 days out and $PYPD still trades like a name nobody bothered to check Nov 28 PDUFA, Priority Review. D PLEX100 for preventing surgical site infections after colorectal surgery Phase 3 SHIELD II cut those infections 60 percent versus standard care, p equals 0.0013, and FDA flagged no filing issues at acceptance imo EMA validated the European filing Oct 1 too. two clocks, one local drug that releases doxycycline for 30 days at the incision. quiet for a setup like that ngl

$PYPD Crazy price. So close to approval, partner, money in the bank, great partnership deal. This should make minimum 100m first year US only. Worth 15 right now. So many biotechs floundering with XBI up. Strange.

$PYPD This guy is a fucking moron. This is a 100m market cap now. With a 300m large partnership and best-in-class treatment. Fuck this guy. Clown

$PYPD if we get the fda, I will double my position under 10 usd a share (atleast going to try) This one is to be held for a decade, I am 22 I have time

35 days out on $PYPD and the quiet part is getting louder Nov 28 PDUFA, Priority Review, D PLEX100 for preventing surgical site infections after colorectal surgery. SHIELD II cut those infections 60 percent versus standard care, p equals 0.0013, and FDA flagged no filing issues at acceptance. then this week brought the microbiology cut, 2,185 patients pooled, heavy bacterial growth in 16 percent on drug plus standard care versus 27 percent on standard care alone. exploratory, sure, but it points the same way as the Phase 3. closed Friday at 5.25, up 2.3 percent, up about 7 percent in five sessions. imo a local drug with two regulatory paths open, US in November and Europe validated Oct 1, is not a name to sleep on into that date ngl

$PYPD Current market cap is 100M. Adressable market is in the multi-billions, especially if this becomes the defacto product for most surgeries which it will likely be. 10 bagger here and that’s conservative af.

$PYPD how about we climb up above $5.5 and hold... and then we keep rising up towards the Nov deadline? Please, and thank you

$PYPD I'm very glad i kept an eye on this stonk for a time so i could buy in at that 4,3 dip and make good profits in the future 😎.

$PYPD Market Maker doing it’s thing- no one really selling most shares are in strong hands - MM make money up or down . We dont care - stay focused on FDA approval. The company already making signals of a platform not just a one product…. Company. Make the math and if you are here consider yourself a lucky one.

$PYPD manufacturing facility inspection end of Oct press release in early November according to company

$PYPD ok just spoke to company . They said they have delivered no stock to any of the people that did the finance ing they are not sellers. Here is how the paper is structured 1 common 1 warrant they are attached and priced at 4.50 if u sell the common u lose the warrnt. I believe there are 7 million shrs the company has control of all this paper and reiterate no seller's no stock delivery. So who the hell is selling great news trading at 5.50 and slammed at the close to 5.10 i have no answers just ? So i guess this post is useless oh well

$PYPD The FDA does not issue separate "PAI approvals" before the PDUFA date, so any official confirmation on the manufacturing facility will only come inside the final approval package.

📅 CATALYST REMINDER | $PYPD October 28, 2026 — Investor Day PolyPid will outline pipeline strategy, discuss D-PLEX under FDA review and introduce the PD01B candidate during its virtual Investor Day. More details in our hub. #PYPD #Biotech #InvestorDay